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Background: The quasispecies composition of Hepatitis C virus (HCV) could have important implications with
regard to viral persistence and response to interferon-based therapy. The complete NS5A was analyzed to evaluate
whether the composition of NS5A quasispecies of HCV 1a/1b is related to responsiveness to combined interferon
pegylated (PEG-IFN) and ribavirin therapy.
Methods: Viral RNA was isolated from serum samples collected before, during and after treatment from virological
sustained responder (SVR), non-responder (NR) and the end-of-treatment responder patients (ETR). NS5A region was
amplified, cloned and sequenced. Six hundred and ninety full-length NS5A sequences were analyzed.
Results: This study provides evidence that lower nucleotide diversity of the NS5A region pre-therapy is associated
with viral clearance. Analysis of samples of NRs and the ETRs time points showed that genetic diversity of
populations tend to decrease over time. Post-therapy population of ETRs presented higher genetic distance from
baseline probably due to the bottleneck phenomenon observed for those patients in the end of treatment. The
viral effective population of those patients also showed a strong decrease after therapy. Otherwise, NRs
demonstrated a continuous variation or stability of effective populations and genetic diversity over time that did
not seem to be related to therapy. Phylogenetic relationships concerning complete NS5A sequences obtained from
patients did not demonstrate clustering associated with specific response patterns. However, distinctive clustering
of pre/post-therapy sequences was observed. In addition, the evolution of quasispecies over time was subjected to
purifying or relaxed purifying selection. Codons 157 (P03), 182 and 440 (P42), 62 and 404 (P44) were found to be
under positive selective pressure but it failed to be related to the therapy.
Conclusion: These results confirm the hypothesis that a relationship exists between NS5A heterogeneity and
response to therapy in patients infected with chronic hepatitis C.Background
Hepatitis C virus (HCV) is the major etiological agent of
chronic hepatitis worldwide [1]. Chronic infection can
progress to liver cirrhosis with risk for the development of
hepatocellular carcinoma [2,3].
The current treatment for chronic hepatitis C is based
on interferon (IFN) or pegylated IFN in combination with
ribavirin (RBV), leading to a sustained virological response
in approximately 50% of patients infected with genotypes
1a/1b [4,5]. Several host parameters, disease characteristics* Correspondence: imvgcmello@gmail.com
2Division of Gastroenterology Laboratory of Applied Molecular Hepatology,
Hepatitis Section, Federal University of São Paulo, São Paulo, SP, Brazil
Full list of author information is available at the end of the article
© 2013 Jardim et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand virus-related factors are relevant to the possibility of
viral clearance after therapy [6,7].
A member of the family Flaviviridae, HCV is an envel-
oped virus with a positive, single-stranded RNA genome
approximately 9.5 kb in length, encoding a single polypro-
tein of approximately 3000 amino acids that is co- and
post-translationally cleaved by viral and cellular proteases
into structural and non structural proteins [8].
HCV is classified into seven genotypes, HCV-1 to −7,
with each genotype being further subdivided into subtypes
such as HCV-1a and 1b [9,10]. Furthermore, in infected
individuals, HCV circulates as a population of several
closely related viral variants referred to as “quasispecies”
[11,12]. New variants are continuously generated during
viral replication as a result of errors made by the viralLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical and virological characteristics of patients
Patient and type of
treatment responsea
Sex Age HCV
Genotype
Sample Viral Load log
UI/ml
Genetic
Distance
Genetic Distance
from baselineb
Shannon
Entropy
SVR
P05 F 44 1b ● 6.04 0.006 ± 0.001 0.0096
P35 M 40 1a ● 6.25 0.005 ± 0.001 0.0074
P40 M 35 1a ● 6.57 0.004 ± 0.001 0.0042
NR
P08 F 41 1a ● 5.80 0.008 ± 0.001 0.0126
12wt 4.59 0.009 ± 0.001 0.009 ± 0.001 0.0113
14d 6.18 0.011 ± 0.001 0.014 ± 0.002 0.0157
2m 6.46 0.008 ± 0.001 0.014 ± 0.002 0.0103
6m 6.40 0.007 ± 0.001 0.015 ± 0.002 0.0156
P11 M 72 1b ● 6.85 0.017 ± 0.001 0.0235
12wt 3.71 0.007 ± 0.001 0.020 ± 0.003 0.0140
14d 6.27 0.005 ± 0.001 0.032 ± 0.004 0.0134
2m 6.73 0.007 ± 0.001 0.034 ± 0.004 0.0132
6m >7.2 0.012 ± 0.002 0.030 ± 0.004 0.0192
P146 M 21 1a ● 6.92 0.012 ± 0.002 0.0202
12wt 5.54 0.006 ± 0.001 0.014 ± 0.002 0.0097
14d 6.43 0.012 ± 0.001 0.020 ± 0.002 0.0172
2m 6.76 0.012 ± 0.001 0.020 ± 0.002 0.0177
6m 6.96 0.008 ± 0.001 0.017 ± 0.002 0.0119
P44 M 51 1b ● 6.50 0.016 ± 0.002 0.0139
12wt 6.13 0.019 ± 0.002 0.019 ± 0.002 0.0311
14d 6.24 0.014 ± 0.001 0.023 ± 0.003 0.0206
2m 7.18 0.014 ± 0.001 0.023 ± 0.003 0.0216
6m 6.83 0.014 ± 0.001 0.024 ± 0.003 0.0216
ETR
P03 M 39 1a ● 5.95 0.011 ± 0.001 0.0131
28d 4.99 0.004 ± 0.001 0.041 ± 0.005 0.0094
2m 5.39 0.003 ± 0.001 0.039 ± 0.005 0.0058
3m 4.74 0.003 ± 0.001 0.039 ± 0.005 0.0055
4m 5.03 0.002 ± 0.001 0.039 ± 0.005 0.0073
5m 5.26 0.001 ± 0.001 0.038 ± 0.005 0.0033
6m 5.08 0.012 ± 0.000 0.038 ± 0.005 0.0038
P37 M 27 1a ● 6.00 0.005 ± 0.001 0.0137
2m 6.63 0.001 ± 0.001 0.017 ± 0.003 0.0055
3m 6.83 0.002 ± 0.001 0.016 ± 0.003 0.0038
4m 6.30 0.003 ± 0.001 0.016 ± 0.003 0.0066
5m 6.10 0.009 ± 0.001 0.017 ± 0.003 0.0074
6m 6.58 0.014 ± 0.001 0.019 ± 0.003 0.0109
P42 M 56 1b ● 6.66 0.016 ± 0.002 0.0161
4m 6.24 0.014 ± 0.002 0.030 ± 0.003 0.0162
5m 6.28 0.017 ± 0.002 0.028 ± 0.003 0.0141
6m 6.34 0.022 ± 0.002 0.030 ± 0.003 0.0145
P47 M 47 1a ● 6.05 0.033 ± 0.002 0.0268
2m 5.67 0.027 ± 0.003 0.039 ± 0.004 0.0466
3m 5.92 0.003 ± 0.002 0.039 ± 0.004 0.0391
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Table 1 Clinical and virological characteristics of patients (Continued)
4m 5.57 0.011 ± 0.001 0.037 ± 0.004 0.0072
5m 5.87 0.009 ± 0.002 0.038 ± 0.004 0.0197
6m 2.93 0.011 ± 0.002 0.041 ± 0.004 0.0171
aSVR, sustained virological response; NR, non-response; ETR, end-of-treatment response.
●=before treatment; wt=weeks of treatment; d=days after the end of treatment; m=months after the end of treatment.
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ing activity, during rapid replication [13]. The quasispecies
nature of HCV could have important implications for viral
persistence, pathogenicity and resistance to anti-viral agents
[14,15].
The non-structural 5A (NS5A) protein is implicated in
interferon resistance [16]. Enomoto et al. [17,18] suggested
that the genetic heterogeneity of a specific domain of the
NS5A region of HCV, termed the IFN sensitivity determi-
ning region (ISDR), was related to treatment responses in
Japanese patients with HCV genotype 1b infection. This is
a controversial issue, but analysis of published information
supports the hypothesis that a relationship exists between
NS5A heterogeneity and response to therapy [19-22].
NS5A is an RNA binding phosphorylated protein com-
prising three domains separated by trypsin-sensitive low
complexity sequences (LCS I and LCS II) and an N-
terminal amphipathic alpha-helix that anchors the protein
to intracellular membranes [23-25]. Full-length NS5A
protein appears to be located exclusively in the cytoplasm.
However, N-terminal deleted forms have been found in
the nucleus, suggesting that they can move to the nucleus
and act as potent transcriptional activators [26-28].
The NS5A region has generated much interest owing to
its association with responses to therapy. In the present
study, the evolution of the complete NS5A region of HCV
genotypes 1a and 1b was examined in patients undergoing
pegylated IFN plus ribavirin therapy. The results demon-
strate that higher diversity and complexity of quasispecies
are related to lower rates of response to peginterferon and
ribavirin therapy. Therefore, quasispecies variability of the
NS5A region could help understand the mechanism
underlying treatment failure in patients infected with
chronic hepatitis C.
Results
Patient characteristics
The characteristics of the patients are presented in Table 1.
The population was predominantly male (NR 75% vs. SVR
67% vs. ETR 100%); 55% of patients were infected with
HCV genotype 1a (NR 25% vs. SVR 67% vs. ETR 75%) and
45% of patients were infected with HCV genotype 1b
(NR 75% vs. SVR 33% vs. ETR 25%). The mean age of the
patients was 43 ± 13.9 years (NR 46.3 ±10.6 vs. SVR 39.7 ±
2.6 vs. 42.3 ± 6.2). No statistically significant differences
were observed between groups.The levels of viremia in baseline samples did not differ
significantly among the patient groups (NR 6.52 vs. SVR
6.39 vs. ETR 6.17 log IU/ml). Patients who did not respond
to therapy had a significant decrease in viremia after 12
weeks of treatment (4.99 ± 0.94 log IU/ml; p=0.002), with
recovering levels in samples collected after therapy was
complete (6.30 – 6.86 log IU/ml). The viral load values var-
ied among the samples from end of treatment responders.
The mean viremia levels for these patients ranged from
4.99 to 5.90 log IU/ml (Table 1).
Nonsense mutations in the NS5A region are observed
in vivo
Eight nonsense mutations were detected in the NS5A re-
gion after analysis of the 690 sequences dataset, two of
them being common to more than one sequence. Codon
9 nonsense mutation was observed in two clones (before
treatment samples from patients P03 and P40) and codon
84 in three clones (two clones in the P146 6m and one
clone in the P42 4m sample). Nonsense mutations were
also observed in codons 47 (before treatment sample from
P47), 233 (P37 5m) and 399 (P44 12wt) (Figure 1). The
majority of nonsense mutations were detected in Domain
I of the NS5A region (codons 47 and 84), with only one
being located in domain III (codon 399), one in the Alpha
Helix (codon 9) region and one in the Low Complexity
Sequence I Region (codon 233). The numeration of
codons was based on the NS5A protein, the first codon
being the first amino acid coded for in the NS5A genomic
region.
Part of this nonsense mutation could provide a func-
tional NS5A protein. Therefore, the sequences at the N-
terminal region of NS5A in which the nonsense mutation
occurred were analyzed to locate the next methionine
residue. The methionines are highlighted in Figure 1A.
The nonsense mutation 399 was not investigated owing to
the presence of a methionine after it. This sequence could
provide functional proteins despite missing a C-terminal
portion (Figure 1B).
Nucleotide diversity of NS5A and sustained response to
therapy
Shannon entropy analysis showed that the genetic diver-
sity of the NS5A region at baseline was significantly lower
for the SVR group (mean value 0.00706) than for the NR
(0.017529) and ETR groups (0.017427) (p=0.0253 and
Figure 1 Alignment of sequence representation demonstrating the nonsense mutations observed in this study. A) Nonsense mutation at
amino-terminal of the NS5A genomic region, positions 9, 47 and 84. B) One nonsense mutation located at the middle of the NS5A genomic region
position 233, and one nonsense mutation located at the carboxy-terminal of the NS5A genomic region, position 399. Pink boxes indicate nonsense
mutations. The next methionines are highlighted in gray. References sequences for genotypes 1a (H77_NS5A1a) and 1b (HCVJ_NS5A1b) are indicated.
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was also significantly lower for the SVR group (0.0050)
than for the NR (0.0133) and ETR (0.0148) groups (p=0.021
and p=0.022, respectively; Figure 2B). These results demon-
strated that quasispecies of SVR samples at baseline are less
diverse than those of NR and ETR samples.
The mean entropy and genetic distance of during-
treatment samples for NR and after the completion of
therapy for NR and ETR samples were comparable when
the results of each patient were analyzed individually.
Generally, values had a propensity to decrease in samples
collected during and after the end of treatment, but no
profile was detected for patients in the same response
group (Table 1 and Figure 2). However, significant differ-
ences were observed when each group was compared by
the mean genetic distance of two time-points. For NRs,
6m post-therapy variants showed significant lower diver-
sity than baseline quasispecies (baseline: 0.01325 vs 6m:
0.01025; p=0.046). ETRs showed values close to signifi-
cance for mean genetic distance but differences were sig-
nificant when Shannon entropy was analyzed between pre
and 5m post-therapy (mean genetic distance - baseline:
0.01475 vs 5m: 0.005916; p=0.06; Shannon entropy –
baseline: 0.017425 vs 5m: 0.011125; p=0.03) (Figure 2C).
To analyze the effect of therapy on quasispecies popula-
tion over time, the mean of genetic distances between each
time point since treatment outset and the baseline sample
were also calculated (Table 1). Differences among groups
of response were compared. Results showed that post-
therapy populations of ETR patients (0.0316) presentedsignificantly higher diversity from baseline variants than
NR patients (0.0222) (p=0.006 (Figure 2D). When during
and after-therapy variants of NRs were compared to ETRs
post-treatment variants, results were also statistically dif-
ferent (0.0205 and 0.0316, respectively; p=0.000).
In order to evaluate the number of NS5A quasispecies in
each sample, all sequences in this study were analyzed using
LOCQSPEC 1.0 software. Figure 3 presents LOCQSPEC
1.0 analyses for ETR and NR patients. The percentages of
different quasispecies in ETR, NR and SVR samples are
presented.
There was no specific profile of quasispecies diversity.
However, samples from ETR patients showed a more var-
ied quasispecies composition before treatment and a more
homogeneous composition in several of the after-treatment
samples. In some cases, the homogenization of quasispecies
composition appeared to be related to the appearance of
predominant quasispecies (Figure 3A). The NR samples
presented with a more heterogeneous quasispecies com-
position than the ETR patient samples. The P08 was the
only patient in whom the same quasispecies were identified
in before- and after-treatment samples (Figure 3B).
The SVR samples contained the most homogeneous
quasispecies composition when compared with ETR and
NR samples collected before treatment (Figure 3C).
NS5A quasispecies experience genetic evolution over time
Phylogenetic trees were reconstructed from 690 full-length
NS5A sequences and reference sequences as described in
the Methods section. Sequences clustered according to
Figure 2 Genetic variability of HCV quasispecies in samples collected over time. A) Genetic complexity calculated using normalized
entropy (Shannon entropy). B) Diversity of HCV quasispecies calculated using genetic distance (p-distance). Patterns of response to therapy are
represented by colours: sustained virological responders in red, non-responders in blue and end-of-treatment responders in green. C) Genetic
diversity by the mean of genetic distance of each time-point collected. On the left: the end-of-treatment-responders. On the right: non-
responders. D) Genetic diversity by the mean of genetic distance between every sample and baseline. Comparisons between non-responders
and end-of-treatment responders. P=value calculated using Fisher’s test or paired t-test.
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1a or 1b references. Viral isolates corresponding to the
same patient samples also clustered, showing they were
more closely related than other patient isolates (Figure 4).
The topology of sequences from each patient was individu-
ally analyzed to evaluate the phylogenetic relationship
among isolates. In general, the phylogenetic analysis sug-
gested clustering of isolates of samples collected before
treatment from ETR patients. The isolates of samples col-
lected at different times after treatment were mixed andgrouped into another cluster. (Additional files 1, 2, 3, 4).
Before treatment, quasispecies clustering was observed for
P146 from NR patients. Sequences from samples collected
before treatment from patients P44, P11 and P08 tended
to group together with quasispecies identified after 12
weeks of treatment. However, bootstrap values only sus-
tained clusters for patient P11 (bootstrap value of 69%).
(Additional files 5, 6, 7, 8).
In some cases, the phylogenetic analysis suggested that
isolates identified in samples collected after treatment
Figure 3 Quasispecies diversity within the NS5A protein based on the number of strains. A) The end-of-treatment responders. B) The non-
responders. C) The sustained virological responders. Vertical bars represent viral variants. Inside the bars are the numbers of identical clones and, consequently,
the number of identical quasispecies. The predominant quasispecies identified from the samples of each patient are identified by specific colors. The
percentages of different quasispecies in ETR, NR and SVR samples are presented above the bars. The time of sample collection are indicated below the bars.
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(Additional Information).
The Skyride analysis shows the variation of effective
populations relative to the genetic diversity of each time-
point analyzed. In general, a strong decrease of relative
populations was observed after therapy for ETR patients.For patients P42 and P37 this variation occurred during
the first 6 months showing a trend to recover then. Alter-
natively, patients P03 and P47 presented a later decrease
of post-therapy populations. Non-responders P08 and
P146 showed a continuous variation over time that did
not seem to be related to therapy and P11 and P44
Figure 4 Unrooted phylogenetic trees reconstructed from the complete NS5A region. Phylogenetic tree reconstructed using the
maximum-likelihood (ML) method, a heuristic search with Nearest Neighbor Interchange (NNI) branch-swapping algorithm. A) HCV genotype 1b
tree was based on the TVMef+G substitution model. B) HCV genotype 1a tree was based on the GTR+G substitution model. References are
utilized in both trees. Patterns of response are represented by colors: sustained virological responders in red, non-responders in blue and end-of-
treatment responders in green.
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Figure 5 Effective quasispecies populations among time-point analyzed. Skyride plots showing the relative genetic diversity of populations
from patients ETR (A) and NR (B). The Black lines represent the median posterior distribution while blue shaded areas are the 95% Bayesian
credible intervals. Red lines represent the start of the treatment.
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(Figure 5).
NS5A quasispecies are under relaxed purifying selective
pressure
Phylogenetic trees were reconstructed using DNA align-
ment of pre and post-therapy NS5A sequences corre-
sponding to each patient in the study. The set of
sequences relative to a specific patient was subjected to
phylogenetic reconstruction by maximum likelihood. Asa result, eight individual phylogenetic trees were gener-
ated (Additional files 1, 2, 3, 4, 5, 6, 7, 8). In order to test
whether selection pressure varied among different
clades, one or two clades of interest were selected for
testing. Clades with predominant quasispecies and those
in which isolates identified in samples collected after
treatment that demonstrated the longest distances from
the main nodes were selected, making the assumption
that the clade of interest would demonstrate different
values of ω (dN/dS) from other branches of the tree. For
Table 2 Log likelihood values and parameter estimated
under two models of selection pressure within particular
clades of NS5A quasispecies
Patient Model l 2Δl Estimates
P08 one-ratio −4404.76677 ωB = 0.1692
two-ratio −4404.28734 0.9587 ωB = 0.1521
ωF = 0.1872
P11a one-ratio −4558.41000 ωB = 0.1835
two-ratio −4552.47248 **11.8750 ωB = 0.1650
ωF = 0.5783
two-ratio −4553.77795 **9.264 ωB = 0.1419
ωF = 0.2685
P146 one-ratio −4755.95340 ωB = 0.1705
two-ratio −4755.92063 0.0822 ωB = 0.1727
ωF = 0.1618
two-ratio −4754.96926 1.9683 ωB = 0.1818
ωF = 0.1246
P44 one-ratio −6356.59235 ωB = 0.1433
two-ratio −6356.28458 0.6155 ωB = 0.1338
ωF = 0.1521
P03 one-ratio −3854.07081 ωB = 0.2003
two-ratio −3853.33452 1.4726 ωB = 0.1977
ωF = 0.2350
P42 one-ratio −5111.91233 ωB = 0.1101
two-ratio −5111.91231 0.0004 ωB = 0.1102
ωF = 0.1101
P47a one-ratio −5455.19420 ωB = 0.2013
two-ratio −5451.97704 *6.4343 ωB = 0.1604
ωF = 0.2487
two-ratio −5444.44505 **21.4983 ωB = 0.1776
ωF = 0.7177
Non-responder: P08, P11, P146, P44; End-of-treatment responder: P03, P42, P47.
X2 critical values, 1 df: *: 3.84; **: 6.63; 2Δ ℓ = 2 (l1-l0).
The ω values considered are presented in bold.
a Two clades selected for analyses.
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clade; the detailed results are presented in Table 2. The
values of ω ranged among patients from ω = 0.1101 to ω
= 0.7177, and the majority of values indicated a purifying
selection or relaxed purifying selective pressure. For
patients P47 and P11, the foreground ω values were sta-
tistically different from the background ones. For these
patients, two clades were selected for analysis using
phylogenetic topology. For patient P47 these were clade
one, where post-therapy quasispecies demonstrated the
longest distances, and clade two, where predominant
quasispecies were grouped. Accordingly, their ω values
were different (clade 1: ωF = 0.2487, 2Δl = 6.4343, andclade 2: ωF = 0.7177, 2Δl = 21.4983). For patient P11,
clade one, where post-therapy quasispecies were located,
and clade two, where quasispecies from the first sample
collected after the end of therapy were grouped, were
selected for analysis. The ω values were different for each
of these clades (clade 1 ωF = 0.2685, 2Δl = 9.264, and
clade 2 ωF = 0.5783, 2Δl = 11.8750). These results indicate
a relaxed purifying selection, with the exception of ωF =
0.7177, which approximates to neutral evolution.
Analysis of selection pressure per site also revealed that
populations were mainly under purifying selection and no
significant difference between response groups was
observed regarding the number of sites selected (NRs 106
and ETRs 103; ω < 1). Sites under positive selective pres-
sure were found at codons 157 (P03), 182 and 440 (P42),
62 and 404 (P44). Data not showed.
Discussion
Quasispecies composition appears to be important in the
IFN resistance mechanisms [29], and genetic variability has
been studied mainly in E2 and NS5A regions of the HCV
genome [30-35]. Additional investigation of NS5A region
variability may be relevant as heterogeneity in this region
before treatment has been related to IFN-monotherapy re-
sponsiveness. However, studies have presented controver-
sial data and the mechanism underlying how NS5A
interferes with responsiveness to treatment has yet to be
elucidated.
In the present study, the genetic variability of the
complete NS5A region in patients infected with HCV
genotype 1 was analyzed. Altogether, 690 sequences of the
entire NS5A from 11 patients’ samples were analyzed.
Samples showed lower genetic diversity of quasispecies
composition at baseline for SVR patients than NR and
patients who relapsed after the end of therapy (ETR).
Those significant differences among genetic distance of
before treatment were not observed in our previous work
when we exclusively analyzed baseline samples [36]. How-
ever, the group of patients and sequences analyzed were
not identical, being only part of sequences of previous
work used to these analyses.
Our findings are consistent with previous observations
made on patients undergoing anti-HCV therapy that less
complexity and lower diversity of HCV quasispecies at the
baseline is associated with viral clearance [19,21,37-39].
Therefore, high genetic variability of HCV could be related
to the low efficiency of anti-HCV treatment [22]. Jain
et al. observed that the initial anti-viral effect of interferon
is influenced by the quasispecies composition at the time
of treatment initiation, and patients who demonstrated
high viral diversity were less likely to respond to treatment
[21]. In agreement with the genetic distance and entropy
results, the number of viral strains at baseline was lower
for SVR patients than NR and ETR patients, showing that
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other groups of responses. A recent study evaluating the
clinical and virological parameters that could be associated
with or predictive of therapy outcome at baseline demon-
strated that a higher number of quasispecies variants in
the E1/E2 region was significantly associated with treat-
ment failure. However, it is inferred that independent fac-
tors cannot provide a consistent prediction of therapy
response [40].
In order to investigate whether therapy caused a signifi-
cant change in the population over time, we compared
variants heterogeneity of baseline, during therapy and
follow-up by analyzing the mean of genetic distance and
Shannon entropy among each time-point. No specific pro-
file of quasispecies diversity for all patients from each
response type could be identified over time. However, sig-
nificant differences were observed when baseline and
post-therapy variants of NRs and ETRs were compared. In
either case post-therapy population were significant less
heterogeneous than baseline showing a decrease of diver-
sity over time.
We also calculated the mean of genetic distances bet-
ween each two time points and could observe that when
compared to the baseline, post-therapy populations of
ETR patients presented significantly higher diversity from
baseline variants than NR patients.
Those findings correlate with data obtained by tracking
the number of strains. Analyzing ETR, it was evident that
quasispecies composition was more homogeneous in post-
therapy samples. This homogeneity was most evident in
patients P37 and P03, who presented with homogeneous
quasispecies composition from the rebound and sustained
it. As with ETR patients, the HCV RNA is undetectable by
the end of therapy, suggesting that the selective pressure of
treatment acts on quasispecies diversity during it until
HCV becomes undetectable in samples. One explanation
is that during or after the end of therapy predominant qua-
sispecies rise in frequency, while others decrease progres-
sively in frequency or are eliminated. The persistence of
this predominant variant could be favorable for sustaining
the infection, causing it to become chronic again.
Farci at al. evaluated the quasispecies composition of
the E1/E2 region in samples from patients who were un-
treated or treated with conventional IFN combined with
ribavirin. Analyzing samples of relapse patients, they
observed greater viral diversity at baseline, and an emer-
gence at relapse of a new dominant strain, or the emer-
gence of a minor dominant population [41]. They inferred
that the emergence of a new viral strain after rebound im-
plies that the majority of baseline variants were sensitive
to IFN and that the origin of these new strains is uncer-
tain. The authors concluded that it is probable that very
low levels of virus replication continued to occur despite
the disappearance of viremia [41].A study focusing on breakthrough response pattern,
defined by patients who have an initial response followed
by reactivation whilst receiving IFN therapy, did not
identify quasispecies variants from breakthrough in base-
line samples [42]. This study assumed that HCV variants
sampled at the time of breakthrough represent drug-
resistant quasispecies, and if present at baseline, they
must be present very low frequency. According to the
authors viral breakthrough could be attributed to the se-
lection of pre-existing drug-resistant variants or the
emergence of different quasispecies with reduced sensi-
tivity to IFN. However, the study indicated that selection
is mostly responsible for appearance of drug resistant
quasispecies at breakthrough [42]. As breakthrough and
relapse indicate rebound of infection after undetectable
HCV RNA levels, is reasonable that the results presented
herein are in agreement when considering the quasispe-
cies composition and diversity at breakthrough and re-
lapse time.
The data collected from non-responder samples revealed
a very diverse composition of viral strains over the time
course of the investigation. As described previously, the
high variability of the quasispecies population in these pa-
tient samples might represent a continuous process of
adaptation [43], as these variants were continuously elimi-
nated during and after the end of treatment in most cases.
Alternatively, it could offer the virus some advantage in sus-
taining the infection as a large number of quasispecies may
indicate a better opportunity for virus persistence [44,45].
The analysis of the number of effective populations
among time-point analyzed showed different profiles for
the types of response. A strong decrease of effective popu-
lations was observed after therapy for ETR patients whereas
NRs presented a continuous variation or stability of its
populations over time. Those data are in agreement to nu-
cleotide diversity results where ETRs demonstrated a de-
crease of population number and heterogeneity presenting
more distinct post-therapy variants. In general, populations
of those patients experience a bottleneck phenomenon
after therapy. On the other hand, profiles found to NRs
assent to the continuous high diverse population and a
lower diversity between pre and post-therapy variants prob-
ably due to a minor effect of treatment in variants selection.
Pawlotsky et al. compared pre- and post-therapy NS5A
amino acid sequences from non-responder patients and
demonstrated that most variants from after-treatment sam-
ples were not detected before treatment, whereas most pre-
treatment variants were no longer evident after treatment
[22]. The data presented here agree with their findings,
with the exception of samples from patient P08. In the P08
samples, a variant was identified at baseline (13% of NS5A
amino acid sequences) that was detected after 12 weeks of
treatment and two months after therapy was completed.
Several studies have showed that variants resistant to
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the persistence of these variants in patients who fail to re-
spond suggests the existence of virus strains with inherent
resistance to IFN [41,43].
Consistent with previous observations, phylogenetic
analysis of virus sequences obtained from patients failed
to show any clustering associated with specific response
[34,41,46]. However, the data suggested that pre- and
post-therapy isolates from samples of ETR patients tended
to group together in different branches. For NR samples,
before-treatment quasispecies variants tended to group
with quasispecies found after 12 weeks of treatment,
and post-therapy sequences grouped together in another
branch. The distinctive clustering of pre/post-therapy
sequences had been described previously [22,42,47], de-
monstrating the evolutionary process occurred over time.
In some cases, isolates identified in after-treatment sam-
ples had the longest distances from the main nodes in
phylogenetic analysis. This may suggest that changes can
improve the fitness of quasispecies resulting in a persistent
infection after treatment selection pressure.
To investigate whether quasispecies were under differ-
ential selective pressure over time, we performed analysis
with the set of sequences of each NR and ETR patient. In
general, the results showed that a purifying selection is
driving the evolution of quasispecies over time. In some
cases, the purifying selection was relaxed (clades selected
for patients P11 and P47). In such cases, two scenarios
could be envisaged. Variants undetected in the baseline
sample due its low frequency could increase in frequency
under relaxed selective pressure and consequently be
detected in the after therapy samples for some time. Alter-
natively, those variants could have arisen by mutation dur-
ing treatment increasing in frequency and being detected
then. Relaxed purifying selection may also be indicative of
some codons of the entire protein being under positive se-
lection. However, we failed to identify sites under positive
selection for those patients. Codons under positive selec-
tive pressure observed in this work could not be related to
the therapy outcome and were not present in preferential
position in the NS5A protein. A study analyzing PKR
binding domain and the V3 domain in the NS5A region
identified positively selected sites but also failed to detect
a pattern mechanism for the inefficient response to anti-
viral treatment [48]. Therefore, further analyses are
necessary.
Genetic analyses identified nonsense mutations in the
NS5A sequence of some HCV variants. Nonsense muta-
tions in samples from HCV-infected patients have been
described [34,36,49], but the structural and functional
implications of such mutations detected in vivo are un-
clear. Most of the nonsense mutations detected were
located in the N-terminal region of NS5A (Alpha Helix,
Domain I or Low Complexity Sequence I regions of theNS5A); only one was located in the C-terminal region
(domain III). It is known that N-terminal mutants of
NS5A are preferentially located in the nucleus and are
reported to function as transcriptional regulators. A recent
study using a HCV replicating cell system revealed that
during the life cycle a variety of N-terminally truncated
NS5A fragments are generated [50]. Tests on several of
these truncated NS5A fragments demonstrated that they
were preferentially located in the nucleus or equally dis-
tributed between the cytoplasm and nucleus. The full
length NS5A (1–449) was located in the extra-nuclear
compartment as previously described. However, truncated
forms impaired HCV replication. In contrast, domain III
of the C-terminal NS5A region can be deleted with no or
minimal effect on RNA replication [51,52], but the C-
terminal region residing between amino acid residues 2404
and 2435 of domain III is crucial for virus production [53].
To elucidate the effects of nonsense mutations identified
in the present study, further analysis with HCV replicating
cells is necessary. Truncated NS5A forms observed in pre-
vious studies show drawbacks in terms of replication or as-
sembly, but these effects could be overcome by the
diversity of quasispecies composition.
Conclusions
This study confirms that heterogeneous diversity of qua-
sispecies pre-therapy could be related to a low response to
IFN-based therapy, and that homogeneity of quasispecies
composition at baseline with viral clearance.
The follow-up of patients’ samples showed that genetic
diversity of populations decreased over time. Post-therapy
population of end-of-treatment responders presented
higher genetic distance from baseline probably due to the
bottleneck phenomenon observed for those patients in
the end of treatment. The effective population of those
patients also showed a strong decrease after therapy.
Otherwise, NRs demonstrated a continuous variation or
stability of effective populations and genetic diversity over
time that did not seem to be related to therapy. Quasispe-
cies distribution of NS5A was variable and distinctly clus-
tered over time. In addition, the evolution of quasispecies
over time was subjected to purifying or relaxed purifying
selection showing that the majority of the synonymous
mutations are not being fixed. Some codons were found
to be under positive selective pressure but it failed to be
related to the therapy.
Therefore, the quasispecies composition and evolution
over time are factors to be considered in terms of patient
outcome after combined therapy for chronic hepatitis C.
Methods
Patients
Eleven naïve patients infected chronically with HCV RNA
genotypes 1a or 1b were enrolled from the Hepatology
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cine. Patients with other concomitant liver diseases [hepa-
titis B virus (HBV) or other hepatotropic virus infections,
alcohol abuse, autoimmune hepatitis and hereditary liver
diseases] were excluded. This study was approved by “The
Ethics Committee of the School of Medicine of São José
do Rio Preto”, and written informed consent was obtained
from all patients who consented to their individual data
being included in the manuscript. Plasma samples were
collected before, during and after the end of treatment.
During the 48-week treatment, patients received PEG-
IFN-α-2b (according to body weight) subcutaneously once
a week and RBV daily, taken orally at a dose of 600–1,200
mg (according to body weight).
The patients were classified into three groups according
to their response to therapy: three patients demonstrated
sustained virological response (SVR); four patients were
non-responders (NR) and four patients were end-of-
treatment virological responders (ETR) (Table 1). SVR was
defined as absence of HCV RNA in plasma using qualita-
tive PCR six months after the end of therapy. NR was
defined as continued presence of HCV RNA in plasma
during treatment and six months after the end of treat-
ment. Patients who were HCV RNA-negative at the end of
therapy but experienced a relapse were classified as ETR.
Breakthrough response pattern defined by patients who
have an initial response followed by reactivation whilst re-
ceiving IFN therapy was not analyzed in this study based
on time point analyzed during treatment.
For all patients, one sample before treatment was ana-
lyzed. Additional samples were collected during therapy
(12 weeks of therapy) and after the end of therapy (14 days,
two and six months) for non-responders, and at the relapse
time and then monthly for end-of-treatment responders.
Samples analyzed for each patient are detailed in Table 1.
Samples from the SVR group and before treatment sam-
ples from most patients (P05, P35, P40, P44, P03, P37 and
P42) enrolled in this study were analyzed in a previous
work (identification of patients: P2, P3, P4, P8, P9, P10
and P11 respectively) and were used in this study for com-
parative analyzes of the evolutionary dynamic of quasispe-
cies [36]. Baseline sample of patients P08, P11, P146 and
P47 analyzed in this work were not previously done. Add-
itionally, all samples collected during and after the end of
treatment were exclusively analyzed in this work.
RNA extraction, RT-PCR and NS5A amplification
Total RNA was extracted from 140 μl of plasma using the
commercially available QIAamp Viral RNA Kit (Qiagen,
Uniscience). RNA was reverse-transcribed into cDNA
using a High-Capacity cDNA Archive kit (Applied Biosys-
tems, Foster City, CA, USA) and random primers. The
mixture was incubated at 37°C for two hours. For amplifi-
cation of the entire NS5A region of the HCV genome, anested polymerase chain reaction (PCR) was performed
using the primers described previously [36].
The viral load was quantified using the Cobas TaqMan
HCV Test according to the manufacturer’s instructions.
Cloning and sequencing
PCR products of approximately 1.7 kb were purified and
ligated into the pCR-XL-TOPO-vector using the TOPO XL
PCR cloning kit (InvitrogenTM Life Technologies, Carls-
bad, CA, USA). The ligation products were transformed
into competent cells (InvitrogenTM Life Technologies,
Carlsbad, CA, USA). Fifteen transformants were randomly
chosen for further studies, and plasmid DNA was isolated
from a 3.0-ml broth culture using the GeneJET plasmid
Miniprep Kit (Fermentas). Recombinant pCR-XL-TOPO-
NS5A clones were sequenced using dideoxy terminator
automated sequencing (ABI Prism Ready Reaction Mix;
Applied Biosystems, Foster City, CA, USA) using an ABI
Prism 377 and ABI 3130XL sequencers, according to the
manufacturer’s instructions (Applied Biosystems Inc, Fos-
ter City, CA, USA.). Eight to ten sequencing reactions
were performed for each clone, using flanking primers,
M13 Forward and M13 Reverse (Invitrogen TM Life
Technologies, Carlsbad, CA, USA), internal forward pri-
mers (1aF1 5’CACCAGTGGATAASCTCGGA3’, 1aF2
5’CCCATYAATGCCTACACCAC3’, 1aF3 5’CTGTCYG
CTCCATCTCTCA3’ and 1aF4 5’GARTCAGARAAC
AAAGTGGTG3’ for genotype 1a; 1bF1 5’ATCCT
CTCHAR-CCTTACCAT3’, 1bF2 5’ GRACATTCCCC
RTCAACGC3’, 1bF3 5’ 5’GTCCTRACAG-AATCCACM
GTG3’ and 1bF4 5’CCARTTGTCTGCGCCTTC3’ for
genotype 1b) and internal reverse primers (1aR1 5’ACAT
WGAGCAACACACGAC3’, 1aR2 5’GTTCCC-TTGAGA
GATGGAGC3’ and 1aR3 5’TAGGCATTRATGGGGA
AGGT3’ for genotype 1a; 1bR1 5’ARCARCAGAC
GACGTCCTC3’, 1bR2 5’AGCGGGTCGAAAGAGTCCA
3’ and 1bR3 5’ GAACCGTTTTTGACATGTCC3’ for
genotype 1b).
Genetic and Evolutionary Analysis
All sequences were analyzed with Phred-Phrap programs
[54-56]. These programs analyze the quality of the se-
quences and align them in complete NS5A contigs. This
study generated 585 sequences of full length NS5A from
samples collected during and after treatment and for
patients P08, P11, P146 and P47 also from the sample col-
lected before the beginning of the treatment. In order to
analyze viral evolution along time, 105 sequences from
samples collected before the treatment, previously pub-
lished (Accession numbers: EU309511 - EU309525,
EU309586 - EU309599 and EU309600 - EU309614) [35],
were used in the analyses. Consequently, 690 full-length
NS5A sequences were analyzed in this study, correspon-
ding to 11 patients. The nucleotide sequence contigs
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1b) were aligned using the Clustal X program (version
1.81) [57] and amino acid sequences were obtained. Pri-
mer sequences were removed from all sequences using
the BioEdit program (version 7.0.5.3) [58]. The genetic
distance between pairs of sequences were calculated with
MEGA version 4 or 5 using the p-distance or Tamura Nei
methods [59]. The variability of amino acid residues in
each position (i) was measured by calculating the Shannon
entropy [22]. The entropy value is a measure of the lack of
information at each position of the amino acid sequence.
The Shannon Entropy was calculated at the amino acid
level as follows: H(i) = −(Σf(b,i)log(base 2)f(b,i)), where f
(b,i) is the frequency with which each residue b appears in
position i of the protein. When different groups of viro-
logical response were compared, the value was normalized
by Sn=H/logN, where N is the total number of sequences
analyzed in each sample [58].
For analyzing quasispecies variability, all sequences of
complete NS5A generated in this study were analyzed
using software LOCQSPEC 1.0 [60] and the contigs that
presented the same nucleotide or amino acid sequences
were grouped together. Bayesian skyride plots were per-
formed using the BEAST package [61].To construct the
phylogenetic tree of NS5A variants obtained from the pa-
tient samples, the PAUP* version 4 program was used
[62]. Phylogenetic trees were constructed using the max-
imum likelihood method with the model of substitution,
as determined by hierarchical likelihood ratio test score
criteria in Modeltest 3.06 [63]. Base frequency, gamma
distribution and transition/transversion ratios were deter-
mined (from the data) by Modeltest 3.06. A thousand
replicates were used to test the support given by the data
to the clusters of the tree topology, and bootstrap values
>70 were considered significant [64]. Genetic and phylo-
genetic analyses were performed using the standard geno-
type 1a sequence H77 (NC_004102.1) as a reference and
genotype 1b sequence HCV-J (D90208.1), obtained from
GenBank. The ratio between the relative rate of non-
synonymous substitution to the relative rate of synonym-
ous substitution (ω=dN/dS) measures the strength of
selection acting on a protein-coding gene. Assuming syn-
onymous mutations are subjected to almost strictly neu-
tral selection, ω<1, ω=1, and ω>1 represent negative
selection, neutral evolution, and positive Darwinian selec-
tion, respectively [65]. Site per site ω was calculated by
Single Likelihood Ancestor Counting (SLAC) method
using HyPhy [66]. Maximum likelihood analysis of the se-
quence evolution was performed using the CODEML pro-
gram in the PAML 3.15 software package [67]. Initially,
phylogenetic trees were reconstructed using the max-
imum likelihood method and the HKY model of substitu-
tion, as determined by hierarchical likelihood ratio test
score criteria in Modeltest 3.06 for each dataset of NS5Asequences corresponding to each non-responder and end-
of-treatment responder in this study. The ratios of global
synonymous changes per site (dS) versus replacement
changes per site (dN) for each tree were calculated using
two models described by Yang [68]. The one-ratio model
assumed an equal ω ratio for all branches in the phy-
logeny. The two-ratio model assumed two ω ratios: one
branch for the background (ω B), one for the foreground
branch (ω F = branch of interest) leading to a specific
clade of the phylogenetic trees, specified in the Additional
Information. This analysis makes different assumptions
about the dN/dS ratios for branches of interest relative to
the background dN/dS ratio for all other branches. For in-
stance, the “two-ratio” model assumes that the branches
of interest have a dN/dS ratio that is different from the
background ratio.
Statistical analysis
The results are presented as mean ± SD, or as percen-
tages. Comparisons among the sustained virological
responders, end of treatment responders and non-
responders were determined using Tukey’s or Fisher’s stat-
istical test after performing an one-way ANOVA or Chi
square. A paired t-test was performed to compare means
between two time-points. In all tests, a P value less than
0.05 was considered significant.
Accession numbers
All sequences obtained in this study were submitted to
the GenBank nucleotide sequence database (http://www.
ncbi.nlm.nih.gov/genbank/). Accession numbers: Gen-
Bank:HQ823765 - HQ824349 (sequences obtained in this
study), GenBank:EU309511 - EU309525, GenBank:
EU309586 - EU309599 and GenBank:EU309600 -
EU309614 (sequences generated in a previous study) [35].
Additional files
Additional file 1: Phylogenetic trees reconstructed from sequences
obtained from patient P42 samples. Maximum likelihood tree
reconstructed from full length NS5A region sequences obtained from
samples from patient P42 (ETR) plus reference sequence of genotype 1b
HCV-J. The number of 1000 permuted trees supporting a clade indicated
when that proportion was greater than 70%. The same quasispecies are
colored in red or pink. A sequence with nonsense mutation is colored in
blue. The clade selected for selective pressure analysis is indicated by a
gray line.
Additional file 2: Phylogenetic trees reconstructed from sequences
obtained from patient P03 samples. Maximum likelihood tree
reconstructed from full length NS5A region sequences obtained from
samples of P03 (ETR) plus reference sequence of genotype 1b HCV-J. The
number of 1000 permuted trees supporting a clade indicated when that
proportion was greater than 70%. The same quasispecies are colored in
red. Sequence with nonsense mutation is colored in blue. The clade
selected for selective pressure analysis is indicated by a gray line.
Additional file 3: Phylogenetic trees reconstructed from sequences
obtained from patient P47 samples. Maximum likelihood tree
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samples of P47 (ETR) plus reference sequence of genotype 1b HCV-J. The
number of 1000 permuted trees supporting a clade indicated when that
proportion was greater than 70%. The same quasispecies are colored in
red. Sequence with nonsense mutation is colored in blue. The clades
selected for selective pressure analysis are indicated by a gray line (clade
1, ω = 0.2487 and clade 2, ω = 0.7177).
Additional file 4: Phylogenetic trees reconstructed from sequences
obtained from patient P37 samples. Maximum likelihood tree
reconstructed from full length NS5A region sequences obtained from
samples of P37 (ETR) plus reference sequence of genotype 1b HCV-J. The
number of 1000 permuted trees supporting a clade indicated when that
proportion was greater than 70%. The same quasispecies are colored in
red. Sequence with nonsense mutation is colored in blue.
Additional file 5: Phylogenetic trees reconstructed from sequences
obtained from patient P11 samples. Maximum likelihood tree
reconstructed from full length NS5A region sequences obtained from
samples of P11 (NR) plus reference sequence of genotype 1b HCV-J. The
number of 1000 permuted trees supporting a clade indicated when that
proportion was greater than 70%. The same quasispecies are colored in
red. The clades selected for selective pressure analysis are indicated by a
gray line (clade 1, ω = 0.5783 and clade 2, ω = 0.2685).
Additional file 6: Phylogenetic trees reconstructed from sequences
obtained from patient P44 samples. Maximum likelihood tree
reconstructed from full length NS5A region sequences obtained from
samples of P44 (NR) plus reference sequence of genotype 1b HCV-J. The
number of 1000 permuted trees supporting a clade indicated when that
proportion was greater than 70%. The same quasispecies are colored in
red. Sequence with nonsense mutation is colored in blue. The clade
selected for selective pressure analysis is indicated by a gray line.
Additional file 7: Phylogenetic trees reconstructed from sequences
obtained from patient P146 samples. Maximum likelihood tree
reconstructed from full length NS5A region sequences obtained from
samples of P146 (NR) plus reference sequence of genotype 1b HCV-J. The
number of 1000 permuted trees supporting a clade indicated when that
proportion was greater than 70%. The same quasispecies are colored in
red. Sequence with nonsense mutation is colored in blue. The clade
selected for selective pressure analysis is indicated by a gray line.
Additional file 8: Phylogenetic trees reconstructed from sequences
obtained from patient P08 samples. Maximum likelihood tree
reconstructed from full length NS5A region sequences obtained from
samples of P08 (NR) plus reference sequence of genotype 1b HCV-J. The
number of 1000 permuted trees supporting a clade indicated when that
proportion was greater than 70%. The same quasispecies are colored in
red. The clade selected for selective pressure analysis is indicated by a
gray line.
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